Form 4: Lixte Biotechnology Director Stephen J. Forman Acquires Options in Lieu of Cash Compensation
SEC Form 4
Director Stephen J. Forman acquired 5,851 options to purchase common stock in Lixte Biotechnology Holdings, Inc. in lieu of quarterly cash compensation.
Summary
- On March 31, 2025, Stephen J. Forman, a director of Lixte Biotechnology Holdings, Inc., acquired 5,851 options to purchase common stock.
- These options were granted in lieu of quarterly cash compensation under the Board Compensation Plan.
- The options have an exercise price of $1.21 and expire on March 31, 2030.
- Forman directly owns various other options to purchase common stock at prices ranging from $1.30 to $32.10, with expiration dates between January 6, 2026, and June 30, 2029.
- Forman also indirectly owns warrants through the Stephen Forman Living Trust.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither particularly positive nor negative on its own.
Positives
- The acquisition of options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
- Granting options in lieu of cash compensation can conserve the company's cash reserves.
Industry Context
This filing is a routine disclosure related to insider transactions, common in the biotechnology industry where stock options are frequently used as part of compensation packages.
Stakeholder Impact
- The granting of options to a director could potentially align the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 12/07/2018 | Date of warrants to purchase common stock expiring 12/07/2022 |
| 05/22/2019 | Date of options to purchase common stock expiring 05/22/2024 |
| 01/06/2021 | Date of options to purchase common stock expiring 01/06/2026 |
| 06/30/2021 | Date of options to purchase common stock expiring 06/30/2026 |
| 06/30/2022 | Date of options to purchase common stock expiring 06/30/2027 |
| 05/22/2024 | Expiration date of options to purchase common stock |
| 06/30/2023 | Date of options to purchase common stock expiring 06/30/2028 |
| 06/30/2024 | Date of options to purchase common stock expiring 06/30/2029 |
| 09/30/2024 | Date of options to purchase common stock expiring 09/30/2029 |
| 01/20/2025 | Date of options to purchase common stock expiring 01/20/2030 |
| 03/31/2025 | Date of transaction: Stephen J. Forman acquired options to purchase common stock; also the exercisable date and expiration date of the newly acquired options is 03/31/2030 |
| 03/31/2030 | Expiration date of newly acquired options to purchase common stock |
Keywords
options, director, Lixte Biotechnology, Form 4, beneficial ownership, compensation, Forman, LIXT, stock options, warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.